Patient case: 26-year-old female with Cervical cancer. Genetic variant: STK11. Other conditions: None.

Clinical trial: MRI and CT Scans to Evaluate Invasive Cervical Cancer Before Treating Patients

Summary: RATIONALE: Imaging procedures such as MRI or CT scans may improve the ability to detect cervical cancer and determine the extent of disease.
  PURPOSE: Diagnostic trial to determine the effectiveness of MRI and CT scans in evaluating invasive cervical cancer before treatment of patients.

Detailed description: OBJECTIVES:
  -  Compare the diagnostic performance of magnetic resonance imaging (MRI), computed tomography (CT), and clinical FIGO staging in patients with invasive cervical cancer.
  -  Compare the accuracy of MRI, CT, and clinical FIGO staging in the evaluation of morphologic tumor prognostic factors in FIGO stage IB1 and stage IB2 and greater in these patients.
  -  Examine the value of imaging assessment of tumor prognostic factors (alone or in combination) as predictors of recurrence within 2 years of surgery in these patients.
  -  Evaluate the quality of life in the 12-month period after staging and treatment to potentially change staging accuracy.
  OUTLINE: This is a multicenter study.
  Patients undergo a computed tomography scan with iodinated contrast dye followed by a magnetic resonance imaging scan with or without contrast comprising gadopentetate dimeglumine or vice versa.
  Within 6 weeks of first protocol imaging study, patients undergo one of the following surgeries:
  -  Laparoscopic, transabdominal, or transvaginal hysterectomy
  -  Extrafascial total abdominal hysterectomy
  -  Trachelectomy Quality of life is assessed at 1 and 12 months.
  Patients are followed every 3 months for 1 year and then every 6 months for 1 year.
  PROJECTED ACCRUAL: A total of 465 patients will be accrued for this study within 18 months.

Eligibility: DISEASE CHARACTERISTICS:
  -  Histologically confirmed invasive cervical cancer, including invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
  -  FIGO stage IB1 with clinically visible gross lesion OR
  -  FIGO stage IB2 or greater
  -  Scheduled for one of the following surgeries at a participating Gynecological Oncology Group center:
  -  Laparoscopic, transabdominal, or transvaginal hysterectomy
  -  Extrafascial total abdominal hysterectomy
  -  Trachelectomy
  -  Not scheduled for a loop electrosurgical excision procedure or a cone biopsy only
  PATIENT CHARACTERISTICS:
  Age:
  -  Not specified
  Performance status:
  -  Not specified
  Life expectancy:
  -  Not specified
  Hematopoietic:
  -  Not specified
  Hepatic:
  -  Not specified
  Renal:
  -  Not specified
  Cardiovascular:
  -  No cardiac pacemakers
  Pulmonary:
  -  No asthma
  Other:
  -  Not pregnant
  -  No contraindication to computed tomography (CT) (e.g., history of allergy to CT contrast medium)
  -  No contraindication to magnetic resonance imaging (e.g., intracranial vascular clip)
  -  No nonmalignant general medical or psychiatric condition that would preclude consent or surgery
  PRIOR CONCURRENT THERAPY:
  Biologic therapy:
  -  Not specified
  Chemotherapy:
  -  No prior chemotherapy
  Endocrine therapy:
  -  Not specified
  Radiotherapy:
  -  No prior radiotherapy for invasive cervical cancer
  Surgery:
  -  See Disease Characteristics
  -  No prior surgery for invasive cervical cancer
  Other:
  -  No prior medical treatment for invasive cervical cancer

Relevance to patient case: not relevant